skip to main content
Idioma:
Resultados 1 2 3 next page
Refinado por: Nome da Publicação: Value In Health remover Academic Search Premier (EB_SDU_P3) remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
PHP139 - 2017 Black Box Amnog Rebates: What Is Driving The Rebates?
PHP139 - 2017 Black Box Amnog Rebates: What Is Driving The Rebates?
Material Type:
Artigo 		Adicionar ao Meu Espaço

PHP139 - 2017 Black Box Amnog Rebates: What Is Driving The Rebates?

Freiberg, M ; Schwarz, R

Value in health, 2017-10, Vol.20 (9), p.A676-A676 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
2
2017 Black Box Amnog Rebates: What Is Driving The Rebates?
2017 Black Box Amnog Rebates: What Is Driving The Rebates?
Material Type:
Artigo 		Adicionar ao Meu Espaço

2017 Black Box Amnog Rebates: What Is Driving The Rebates?

Freiberg, M ; Schwarz, R

Value in health, 2017-10, Vol.20 (9), p.A676 [Periódico revisado por pares]

Lawrenceville: Elsevier Science Ltd

Texto completo disponível

Citações Citado por
3
PSY145 - How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?
PSY145 - How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?
Material Type:
Artigo 		Adicionar ao Meu Espaço

PSY145 - How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?

Schwarz, R ; Freiberg, M

Value in health, 2016-11, Vol.19 (7), p.A600-A600 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
4
How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?
How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?
Material Type:
Artigo 		Adicionar ao Meu Espaço

How Does the Additional Benefit Extend of Orphan Drugs Impact Price Negotiations in the German Outpatient Sector?

Schwarz, R ; Freiberg, M

Value in health, 2016-11, Vol.19 (7), p.A600-A600 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
5
PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY
PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY
Material Type:
Artigo 		Adicionar ao Meu Espaço

PMD39 HOSPITAL REIMBURSEMENT PATHWAYS FOR NEW EXAMINATION AND TREATMENT METHODS IN GERMANY

Worf, K. ; Schuh, I. ; Scheler, E. ; Schwarz, R. ; Bonduelle, D.

Value in health, 2019-11, Vol.22, p.S676-S676 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
6
Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany
Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany
Material Type:
Artigo 		Adicionar ao Meu Espaço

Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany

Freiberg, M ; Schwarz, R ; Khoury, C

Value in health, 2016-11, Vol.19 (7), p.A442-A442 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
7
PHP16 - Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany
PHP16 - Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany
Material Type:
Artigo 		Adicionar ao Meu Espaço

PHP16 - Biosimilars: Market Access and Market Penetration – A Comparison of France and Germany

Freiberg, M ; Schwarz, R ; Khoury, C

Value in health, 2016-11, Vol.19 (7), p.A442-A442 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
8
PHP206 - How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?
PHP206 - How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?
Material Type:
Artigo 		Adicionar ao Meu Espaço

PHP206 - How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?

Freiberg, M ; Schwarz, R ; Fath, F

Value in health, 2015-11, Vol.18 (7), p.A550-A550 [Periódico revisado por pares]

Elsevier Inc

Texto completo disponível

Citações Citado por
9
How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?
How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?
Material Type:
Artigo 		Adicionar ao Meu Espaço

How Does The Additional Benefit Extent of Orphan Drugs Impact Price Negotiations In The German Outpatient Sector?

Freiberg, M ; Schwarz, R ; Fath, F

Value in health, 2015-11, Vol.18 (7), p.A550-A550 [Periódico revisado por pares]

United States

Texto completo disponível

Citações Citado por
10
Update on Impact of The Additional Benefit Extent of Orphan Drugs on Price Negotiations In The German Outpatient Sector
Update on Impact of The Additional Benefit Extent of Orphan Drugs on Price Negotiations In The German Outpatient Sector
Material Type:
Artigo 		Adicionar ao Meu Espaço

Update on Impact of The Additional Benefit Extent of Orphan Drugs on Price Negotiations In The German Outpatient Sector

Freiberg, M ; Schwarz, R ; Schalk, E ; Kraft, T

Value in health, 2017-10, Vol.20 (9), p.A568 [Periódico revisado por pares]

Lawrenceville: Elsevier Science Ltd

Texto completo disponível

Citações Citado por
Resultados 1 2 3 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.